A pproximately 45 to 56% of patients with congestive heart failure (CHF) and a left ventricular ejection fraction (LVEF) of Ͻ 45% have CheyneStokes respiration (CSR) during sleep. [1] [2] [3] [4] Character-
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ized by a crescendo-decrescendo alteration in tidal volume separated by periods of apnea or hypopnea, CSR has been associated with an increased mortality in patients with CHF. 2, 5, 6 We have demonstrated that nasal continuous positive airway pressure (CPAP) and oxygen therapy were equally effective at decreasing the apnea-hypopnea index (AHI) in patients with CSR and CHF. 4 Yet, the mechanism(s) by which these treatment modalities improve CSR is uncertain and may involve increasing total body oxygen stores (dampening), changes in central and peripheral controller gain, and/or improvement in cardiac function. In particular, it has been suggested that nasal CPAP is effective by decreasing interstitial edema and pulmonary vagal afferent stimulation, resulting in a decrease in central and peripheral controller gain. [7] [8] [9] But an increased controller gain does not appear to be the sole mechanism responsible, as not all patients with CHF and CSR demonstrate an increased sensitivity to CO 2 . 10, 11 Dampening refers to the ability of the body to stabilize Pao 2 and Paco 2 during changes in ventilation. In patients with CHF, interstitial edema causes a decrease in functional residual capacity (FRC), 12 leading to a decrease in total body oxygen and CO 2 stores. As a result, the respiratory system becomes unstable (underdampened), with exaggerated changes in Pao 2 and Paco 2 during transient changes in ventilation. CSR can develop as a result of these changes in blood gas tensions.
The rate of fall of arterial oxyhemoglobin saturation (dSao 2 /dt) has been shown to correlate with total body oxygen stores and is dependent on thoracic volume, resting total body oxygen consumption (V o 2 ), preapneic arterial oxygen saturation (Sao 2 ), and mixed venous oxygen saturation (Svo 2 ). [13] [14] [15] [16] [17] [18] [19] We prospectively studied a group of patients with severe CHF (LVEF Ͻ 40%) and CSR to evaluate the effects of nasal CPAP on total body oxygen stores, as measured by dSao 2 /dt, to determine if dampening may play a role in the attenuation of CSR; and to determine which factors correlate with dSao 2 /dt in patients with CSR and CHF.
Materials and Methods

Patient Selection
Nine male patients with severe CHF (New York Heart Association class IV) were studied in a nonblinded manner. Patients were all in medically stable condition for at least 1 month prior to the start of the study, with no change in their treatment regimens during the study period. The patients were all known to have CSR, as identified during a baseline polysomnographic study as part of a previous study. 4 Patients were excluded from the study for the following: (1) if there was an episode of acute pulmonary edema within 1 month prior to the study, (2) if there was a history of a cerebral vascular accident, or (3) if patients refused to complete all the required polysomnographic studies. Our institutional review board approved the protocol, and informed consent was obtained from all patients prior to the study.
Patients were admitted to a special inpatient heart failure unit where they were evaluated and listed for heart transplantation, as previously described. 4 The patients' treatment regimens were optimized, and all patients were ambulatory and participating in physical conditioning classes at the time of the study.
Cardiac Hemodynamics and Echocardiography
All patients underwent right-heart catheterization within 1 month of the study. Parameters that were obtained included measurement of right atrial pressure, pulmonary artery pressure, and pulmonary capillary wedge pressure. In addition, cardiac output was measured as the mean of three recordings using thermodilution technique. An echocardiogram was also obtained on each patient to determine LVEF.
Therapeutic Interventions
All patients were acclimated to nasal CPAP (REMstar; Respironics; Murrysville, PA) during the daytime prior to their study night, as previously described. 4 In brief, patients received nasal CPAP bid for 1-to 2-h periods while awake at an initial pressure of 5 cm H 2 O. During a 5-to 7-day period, nasal CPAP was increased 2 cm H 2 O/d toward a goal of 10 to 12 cm H 2 O, as tolerated. Nasal CPAP was administered during the study night at the maximal determined pressure (9 Ϯ 0.3 cm H 2 O).
Sleep Studies
Polysomnography consisted of recordings of abdominal and rib cage motion (Resp-EZ; EPM Systems; Midlothian, CA), finger pulse oximetry (model N-100; Nellcor Puritan Bennett; Pleasanton, CA), oral and nasal thermistors, ECG, electro-oculogram, digastric electromyogram, and EEG. The pulse oximeter used a signaling average of 5 to 7 s, similar to previous studies measuring dSao 2 /dt. 20 All variables were recorded continuously and stored on a computerized system (Alice 3; Healthdyne Information Enterprises; Marietta, GA). Sleep stage was classified by the standard criteria of Rechtschaffen and Kales. 21 Total sleep time (TST), and sleep efficiency (defined as TST divided by time in bed) were also determined. Arousals were defined as the appearance of ␣ activity for 3 to 15 s. 22 Central apneas were defined by the lack of airflow for Ͼ 10 s, associated with the absence of rib cage and abdominal movement.
Central hypopneas were defined by a 50% decrease in airflow for Ͼ 10 s, associated with a decrease in rib cage and abdominal excursion and a lack of abdominal-rib cage paradox. The central AHI was expressed as the number of apneas and hypopneas per hour of sleep. CSR was determined to be present when the central AHI was Ն 10 events per hour, 7 with events associated with a crescendodecrescendo alteration in breathing pattern characteristic of CSR. dSao 2 /dt was measured as the slope of a line drawn adjacent to the falling linear portion of the Sao 2 curve associated with a central apnea (Fig 1) . 17, 18 The Sao 2 prior to the linear fall in Sao 2 is referred to as the preapneic Sao 2 (Fig 1) , and the postapneic Sao 2 refers to the Sao 2 at the flattened portion of the curve, following the linear descent (Fig 1) . For each study, the dSao 2 /dt, preapneic Sao 2 , and postapneic Sao 2 were determined by calculating the mean of 10 consecutive measurements obtained during an episode of CSR. The 10 consecutive apneas were chosen during the second sustained episode of CSR, during the first half of the night, while the patient was in stable stage 2 sleep. There were no awakenings or movement times during the sequence of CSR that was utilized for the measurements.
Protocol
All patients underwent baseline polysomnography that identified the presence of CSR. Repeat polysomnography while administering nasal CPAP at the maximized tolerated pressure was then performed 12 Ϯ 6 days after the baseline study. All patients were in stable condition with no change in their medical regimens between the two studies.
Statistical Analysis
Data are represented as mean Ϯ SD. Paired t tests were used to compare baseline variables to those obtained with nasal CPAP.
The relationship between dSao 2 /dt and the preapneic Sao 2 , postapneic Sao 2 , and AHI were assessed by Pearson correlation coefficients.
Results
Patient Characteristics
Nine male patients (mean age, 59 Ϯ 8 years; body mass index [BMI], 28 Ϯ 6) were studied ( Table 1) . The mean LVEF was 16 Ϯ 4% on a maximized treatment regimen, which included a continuous infusion of an inotropic agent. Baseline cardiac hemodynamics demonstrated a cardiac index of 2.5 Ϯ 0.6 L/min/m 2 , mean pulmonary artery pressure of 31 Ϯ 11 mm Hg, pulmonary capillary wedge pressure of 20 Ϯ 8 mm Hg, and a heart rate of 78 Ϯ 21 beats/min. The baseline AHI was 44 Ϯ 27 events per hour, with a TST of 324 Ϯ 59 min, sleep efficiency of 82 Ϯ 8%, and an arousal index of 14 Ϯ 13 arousals per hour ( Table 1) .
Effects of Nasal CPAP
Nasal CPAP resulted in a significant decrease in the AHI, from 44 Ϯ 27 events per hour at baseline, to 15 Ϯ 24 events per hour with nasal CPAP (p ϭ 0.004). The apnea index significantly decreased with nasal CPAP, from 34 Ϯ 31 to 14 Ϯ 32 events Fig 3) . There was no significant change in the preapneic Sao 2 , from a baseline of 96 Ϯ 2% to 96 Ϯ 3% with nasal CPAP (p ϭ 0.8; Fig 4) . When compared to baseline, there was no significant change in apnea duration with nasal CPAP, from 21 Ϯ 3 to 21 Ϯ 6 s (p ϭ 0.9). Heart rate, when compared to baseline, did not significantly change with nasal CPAP, from 78 Ϯ 21 to 73 Ϯ 16 beats/min, respectively (p ϭ 0.3). At baseline, there was a significant correlation between postapneic Sao 2 and dSao 2 /dt (r ϭ Ϫ 0.8, p ϭ 0.02; Fig 5, top, A) . There was no correlation noted between baseline preapneic Sao 2 and dSao 2 /dt (r ϭ Ϫ 0.1, p ϭ 0.7; Fig 5, bottom, B) . Additionally, a significant correlation was noted between baseline dSao 2 /dt and the AHI (r ϭ 0.7, p ϭ 0.02; Fig 6) . With CPAP, there was a significant correlation noted between dSao 2 /dt and the AHI (R ϭ 0.7, p ϭ 0.04), but no correlation noted between dSao 2 /dt and postapneic Sao 2 (R ϭ Ϫ 0.1, p ϭ 0.8).
Discussion
An increase in total body oxygen stores, resulting in a dampening effect on the respiratory control system, is thought to be responsible for the effectiveness of oxygen in the treatment of CSR in patients with CHF. 23 The effects of nasal CPAP on total oxygen body stores, and thus dampening, in these patients has not previously been investigated. There are three major findings in this study: (1) nasal CPAP significantly reduced dSao 2 /dt in patients with 
*Data are presented as mean Ϯ SD or No. PCWP ϭ pulmonary capillary wedge pressure; REM ϭ rapid eye movement; NYHA ϭ New York Heart Association; ACE ϭ angiotensin-converting enzyme. CSR and CHF; (2) in patients with CHF and CSR, the baseline postapneic but not the preapneic Sao 2 correlated with dSao 2 /dt; and (3) there was a significant correlation between dSao 2 /dt and the AHI. The endogenous stores of oxygen of the body are rather limited (approximately 2 L), as compared to that of CO 2 (120 L), due to differences in tissuebinding affinities. 24, 25 Approximately 25% of the total oxygen stores of the body are contained in the lung and 15% in the tissues, with the majority (60%) contained in the blood due to the binding affinity for hemoglobin. 25 During breath-holding, as well as with central and obstructive apneas, dSao 2 /dt, as a reflection of total oxygen body stores, has been shown to correlate with a number of factors, including thoracic volume, V o 2 , preapneic Sao 2 , and Svo 2 . [13] [14] [15] [16] [17] [18] [19] The volume of oxygen stored in the lungs is equal to lung volume times the alveolar fractional concentration of oxygen. 24 Findley et al 13 examined the impact of lung volume on the fall in Sao 2 during voluntary breath-holding in seven normal males. Initial lung volume was found to be the most important determinant for both the fall in Sao 2 as well as the minimal Sao 2 . The most severe decreases in Sao 2 were noted at lower initial lung volumes (Ͻ 2 to 3 L), more specifically at lung volumes below closing capacity where dependent airways are more susceptible to closure. Similarly, Hurewitz and Sampson 14 demonstrated that lung volume (measured at FRC) was an important determinant for the rate of fall in alveolar oxygen tension during breath-holding. The decrease in alveolar oxygen tension was found to be responsible for the associated decrease in Sao 2 .
Patients with CHF have a restrictive ventilatory pattern with a reduction in lung volumes. 12 By recruiting alveoli and redistributing lung water, positive end-expiratory pressure may increase total oxygen body stores by increasing end-expiratory lung volume. 26, 27 CPAP has been shown to increase lung volumes, including FRC, at levels of 5 to 11 cm H 2 O, 28 -31 which is similar to the mean CPAP level of 9 cm H 2 O used in our patients. Although lung volumes were not directly measured in our study, an increase in FRC could be responsible for the observed decrease in dSao 2 /dt and thus the increase in total oxygen body stores seen with nasal CPAP. The preapneic Sao 2 has been shown to be an important determinant for dSao 2 /dt during breathholding as well as during central and obstructive apneas. 15, 17 Yet, other studies have not demonstrated as strong a correlation between the two variables, 18 and a component of the relationship was attributed to a decrease in lung oxygen stores created by having the subjects breath hypoxic gas mixtures. 15 In the present study, there was no correlation noted between baseline dSao 2 /dt and preapneic Sao 2 . In addition, there was no significant change in preapneic Sao 2 with nasal CPAP. One possible explanation may involve the fact that the preapneic Sao 2 was 96% at baseline, with a further increase in Sao 2 expected to be marginal with nasal CPAP.
Another important determinant of dSao 2 /dt is the preapneic Svo 2 . 17, 18 Since the majority of the oxygen stores of the body are contained in the blood, and 70% of the total blood volume is venous, it is understandable that a change in Svo 2 could effect dSao 2 /dt, especially in the presence of underlying lung disease. In our study, we did not directly measure Svo 2 but we did measure postapneic Sao 2 , which at baseline was found to inversely correlate with dSao 2 /dt (Fig 5, top, A) . Postapneic Sao 2 may influence Svo 2 , especially in patients with CHF where there is an increase in both the circulation time and oxygen extraction. 7 The use of nasal CPAP resulted in a significant increase in postapneic Sao 2 , with a possible corresponding increase in Svo 2 . Although apnea duration may affect postapneic Sao 2 values, nasal CPAP was noted to have no effect on apnea duration in our patients.
With nasal CPAP, an inverse correlation was no longer noted between dSao 2 /dt and postapneic Sao 2 . Yet, it should be noted that with nasal CPAP, the postapneic Sao 2 had increased from 87 Ϯ 5 to 91 Ϯ 4 mm Hg. With an increase in the postapneic Sao 2 to Ͼ 90%, its effect on Svo 2 may be less significant, with other factors, such as lung volume, becoming more important in determining total body oxygen stores.
A decrease in V o 2 could also account for the change in dSao 2 /dt seen with nasal CPAP, but this seems less likely. Differences in body weight are responsible for the correlation between the rate of fall of alveolar oxygen tension and V o 2 noted during breath-holding. 14 Obese subjects have higher preapneic V o 2 measurements and thus a greater rate of fall of alveolar oxygen tensions. In the present study, our patients were not morbidly obese (BMI, 28 Ϯ 6), and thus would not be expected to have an elevated baseline V o 2 . Furthermore, the mechanism(s) by which nasal CPAP would decrease V o 2 is uncertain. Nasal CPAP may increase cardiac output in patient with CHF, 32, 33 with a corresponding increase in oxygen delivery resulting in either no change 34 or an increase 35 
Other mechanisms may be responsible for the decrease in dSao 2 /dt seen with nasal CPAP. As noted, nasal CPAP can have significant effects on cardiac function in patients with CHF. 32, 33 An increase in cardiac output may result in a significant increase in Svo 2 , with a corresponding increase in total oxygen body stores. Others have suggested that a reduction in cardiac output could result in a decrease in dSao 2 /dt, by its effect on the lung to chemoreceptor circulation time. 20 Yet, it has previously been demonstrated that nasal CPAP, at levels similar to those used in the present study, have no effect on circulation time in patients with CSR and CHF. 4 Mechanisms other than underdampening appear to be important in the development of CSR in CHF. An increase in central and peripheral controller gain is thought to be responsible for the hyperventilationinduced resting hypocapnia seen in these patients. [7] [8] [9] [10] [11] With an arousal induced hyperpnea, Paco 2 decreases below the sleeping apneic threshold, resulting in a central apnea. In the presence of an increased central and peripheral controller gain, the ventilatory response to the increase in Paco 2 at the end of an apnea is exaggerated, resulting in the development of CSR. Javaheri 11 demonstrated that the ventilatory response to CO 2 was significantly elevated in those patients with, as compared to those without CSR, despite a similar degree of heart failure. More recently, Solin et al 10 reported that both central and peripheral CO 2 ventilatory responses are increased in patients with CSR as compared to those without CSR, as well as normal control subjects. Yet, in both studies, there was a considerable amount of overlap in the ventilatory response to CO 2 noted between the groups, emphasizing the importance of other mechanisms in the development of CSR. In addition, our study demonstrated a significant correlation between the baseline dSao 2 /dt and the AHI (r ϭ 0.7, p ϭ 0.02; Fig 6) , suggesting that other mechanisms, such as underdampening, may be important in the development of CSR.
Nasal CPAP has been shown to be effective in the treatment of CSR in CHF when used over a variable amount of time. 4, 9, 33, 36 One mechanism that appears to be responsible is the ability of nasal CPAP to increase Paco 2 , so that it remains well above the apneic threshold. Naughton et al 9 demonstrated that 1 month of nasal CPAP resulted in an increase in nocturnal transcutaneous Pco 2 , secondary to a decrease in tidal volume. The authors postulated that an improvement in left ventricular function with nasal CPAP reduced interstitial edema and pulmonary vagal afferent stimulation, resulting in a decrease in central controller gain. Yet, the effects of nasal CPAP on central or peripheral controller gain have not been evaluated. In addition, although there was a decrease in tidal volume, other lung volumes, including FRC, will increase with nasal CPAP, resulting in an increase in the volume of oxygen stored in the lungs. Finally, it is important to note that although both the AHI and dSao 2 /dt decreased with nasal CPAP in our study, the correlation between the two indexes remained significant (R ϭ 0.7, p ϭ 0.04). Therefore, other mechanisms, including a dampening effect, may play a role in the effectiveness of nasal CPAP on CSR in patients with CHF.
There are a number of limitations with our study that need to be discussed. First, none of the variables that determine total oxygen body stores, and thus dSao 2 /dt, including measurement of lung volumes, were evaluated in the present study. Thus, it is uncertain which variables were affected by nasal CPAP that led to the significant attenuation in dSao 2 /dt. Second, the present study evaluated the acute effects of nasal CPAP on dSao 2 /dt. Whether more prolonged therapy will have a similar and sustained effect has yet to be determined. Third, the studies were performed in a nonblinded manner. We believe this did not effect the measurement of dSao 2 /dt, as it was performed in a standardized manner in a sleeping patient. Finally, in addition to apnea duration, the repetitive nature of the apneas may effect dSao 2 /dt, mostly by its effects on preapnea Sao 2 and Svo 2 . 17 The dSao 2 /dt was calculated by taking the mean of 10 consecutive apneas at baseline and while administering nasal CPAP. We found no correlation between the 10 sequential baseline central apneas and their corresponding dSao 2 /dt, for all nine patients individually (data not shown), as well as for the group as a whole (r ϭ Ϫ 0.2, p ϭ 0.6). Therefore, the repetitive nature of the central apneas did not effect total oxygen body stores, and the decrease in dSao 2 /dt observed with nasal CPAP is independent of its effects at decreasing the number of central apneas during the night.
In conclusion, nasal CPAP is effective at decreasing dSao 2 /dt and thus increasing total body oxygen stores in patients with CSR and CHF. By increasing total body oxygen stores, dampening may be one of the mechanisms partially responsible for the attenuation of CSR seen with nasal CPAP. In patients with CSR and CHF, baseline AHI and postapneic but not preapneic Sao 2 correlate with total oxygen body stores, as reflected in the measurement of dSao 2 /dt. Which physiologic variables are affected by nasal CPAP and are responsible for the decrease in dSao 2 /dt, and whether similar findings are seen after more prolonged use, awaits further investigation.
